Patents Assigned to M. L. Laboratories PLC
  • Patent number: 6881556
    Abstract: The present invention relates to a polynucleotide comprising a ubiquitous chromatin opening element (UCOE) which is not derived from 13. The polynucleotide of any one of claims 1 to 7, wherein the UCOE comprises the sequence of FIG. 20 between nucleotides 1 to 7627 or a functional homologue or fragment thereof. an LCR. The present invention also relates to a vector comprising the polynucleotide sequence, a host cell comprising the vector, use of the polynucleotide, vector or host cell in therapy and in an assay, and a method of identifying UCOEs. The UCOE opens chromatin or maintains chromatin in an open state and facilitates reproducible expression of an operably-linked gene in cells of at least two different tissue types.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 19, 2005
    Assignee: M. L. Laboratories PLC
    Inventors: Michael Antoniou, Robert Crombie
  • Patent number: 6297225
    Abstract: A method of treating a patient having a highly vascular tumor includes administering a therapeutically effective amount of dextrin sulphate to the patient. The highly vascular tumor can be, for example, Kaposi's sarcoma. The treatment results in regression of the tumors and the improvement persists for a considerable time after completion of the treatment.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: October 2, 2001
    Assignee: M L Laboratories PLC
    Inventors: Donald Davies, Robert John Edwards, Nigel John Gooderham, Sunil Shaunak
  • Patent number: 6248726
    Abstract: There is described polysaccharides of high molecular weight for use in peritoneal dialysis. The polysaccharides are capable of dialysing human serum for long periods of time without causing damage to the peritoneum and are also capable of preventing loss of polymer from the peritoneum to the serum. There is also described a method of making the polysaccharides and pharmaceutical formulations containing them.
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: June 19, 2001
    Assignee: M L Laboratories plc
    Inventors: Ranulph Michael Alsop, Raymond Brian Forrester, David John Manning
  • Patent number: 5439894
    Abstract: Disclosed is a pharmaceutical composition comprising a dextrin derivative in which a proportion of the hydroxyl groups of dextrin are replaced by basic groups. Such compositions are useful for the treatment of acidic conditions.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: August 8, 1995
    Assignee: M L Laboratories PLC
    Inventor: Donald S. Davies
  • Patent number: 5280017
    Abstract: A method of treating acid poisoning in mammals or of lowering blood cholesterol levels in mammals, which involves administering to the mammals a pharmaceutically effective amount of an aminated dextrin where amine groups or residues are present in an amount of from 0.5 to 2 groups per glucose unit.
    Type: Grant
    Filed: January 29, 1991
    Date of Patent: January 18, 1994
    Assignee: M L Laboratories PLC
    Inventor: Donald S. Davies
  • Patent number: 5258175
    Abstract: A dextrin derivative, in which a proportion of the hydroxyl groups in the dextrin have been replaced by strongly acidic groups, is useful in treatment of poisoning or drug overdose, particularly by compounds having basic groups. Dextrin sulphate is a preferred derivative for use in the treatment of paraquat poisoning.
    Type: Grant
    Filed: January 25, 1991
    Date of Patent: November 2, 1993
    Assignee: M L Laboratories PLC
    Inventor: Donald S. Davies
  • Patent number: 4886789
    Abstract: A peritoneal dialysis composition containing an osmotic agent comprising a glucose polymer mixture, said mixture including at least 15% by weight of glucose polymers having a D.P. (degree of polymerization) greater than 12. A method is provided for preparing the glucose polymers and a defined sterile aqueous solution of the same for use in peritoneal dialysis by introduction into the abdominal cavity. Also disclosed are methods of treating toxaemia caused by toxins arising from internal disorders of the body, such as hepatic encephalopathy, or which arise from external sources such as poisoning by overdoses of drugs or industrial and agricultural chemicals, e.g., paraquat.
    Type: Grant
    Filed: April 10, 1989
    Date of Patent: December 12, 1989
    Assignee: M. L. Laboratories PLC
    Inventor: Jeremiah Milner